KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study. PMID 40025846 · Clin Transl Sci · 2025-Mar The study is a Phase III randomized trial in oncology with a drug intervention, but the primary efficacy endpoint is MRD-negative CR at EOI, a categorical remission rate. The abstract describes exposure-response analyses for efficacy and safety, but does not report any time-to-event endpoints like OS or PFS, nor any Kaplan-Meier analyses or hazard ratios. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer. PMID 40022844 · Int J Gynecol Cancer · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. PMID 40009571 · Clin Transl Sci · 2025-Mar 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Developing and testing health warnings about alcohol and risk for breast cancer: Results from a national experiment with young adult women in the United States. PMID 39985486 · Alcohol Clin Exp Res (Hoboken) · 2025-Mar Study is a randomized experiment testing health warnings about alcohol and breast cancer risk, not a clinical trial of a drug intervention with time-to-event efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study. PMID 39978378 · Lancet Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. PMID 39978376 · Lancet Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. PMID 39978375 · Lancet Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer. PMID 39954390 · ESMO Open · 2025-Mar The study is a secondary analysis of pharmacokinetics and exposure-response from a randomized trial. While it involves oncology, a human randomized trial, a drug, and a time-to-event endpoint, the metadata does not explicitly confirm the trial phase as definitive (Phase III, IIIb, or II/III). Furthermore, as a secondary analysis, it is not the primary report of the trial's efficacy comparison. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer. PMID 39951918 · Gynecol Oncol · 2025-Mar The study is a randomized, drug-intervention trial in human ovarian cancer, but it is not a Phase III or definitive Phase II/III trial, and it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR. The primary objectives are safety, immune activation, and dose optimization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies. PMID 39938189 · Lung Cancer · 2025-Mar The record describes a combined analysis of two prior phase III trials (JIPANG and IMPACT). It is not the original primary result report of a single randomized trial, which is required for inclusion. The analysis itself is a secondary/post-hoc pooling of data, and the publication type is 'Journal Article, Clinical Trial, Phase III', but the content is a cross-trial analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. PMID 39923680 · Gynecol Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Impact of Atorvastatin on Intraprostatic Biomarkers - Prognostic Value of 3LS-score - Follow-up of ESTO1-Trial. PMID 39919693 · Neoplasia · 2025-Mar The record describes a randomized trial of atorvastatin in prostate cancer with time-to-event outcomes, but the trial phase is not confirmed as Phase III/IIIb or Phase II/III. The study is primarily a biomarker-focused trial (impact on intraprostatic biomarkers, prognostic value of 3LS-score), and while it reports long-term clinical outcomes, the primary objective is not drug efficacy in a definitive Phase III setting. Therefore, it does not meet the strict eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neuroendocrine cervical carcinomas: genomic insights, controversies in treatment strategies, and future directions: a NeCTuR study. PMID 39903954 · Int J Gynecol Cancer · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. PMID 39894025 · Lancet Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making. PMID 39869260 · BioDrugs · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer. PMID 39837424 · Radiother Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. PMID 39827019 · Eur Urol · 2025-Mar 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Xenogeneic platelet-rich plasma lotion for preventing acute radiation dermatitis in patients with breast cancer undergoing radiotherapy: An open-label, randomized controlled trial. PMID 39811585 · JPRAS Open · 2025-Mar The study is an oncology human randomized trial with a primary result, but the intervention is a non-drug device/lotion (XONRID® gel is a medical device, PRP lotion is a biological product) and the primary efficacy endpoints are acute radiation dermatitis rates (categorical toxicity), pain scores, and quality-of-life indices, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303. PMID 39809075 · J Geriatr Oncol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study. PMID 39808408 · Target Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study. PMID 39789153 · Br J Cancer · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcome following pylorus resecting pancreaticoduodenectomy versus classical Whipple's pancreaticoduodenectomy: a randomised controlled trial. PMID 39757070 · HPB (Oxford) · 2025-Mar The study is a randomized controlled trial comparing two surgical techniques (pylorus resecting vs. classical pancreaticoduodenectomy) for pancreatic cancer. It meets oncology, human, randomized, and original result criteria. However, it is not a Phase III or definitive trial (phase is not specified), lacks a drug-containing intervention (surgical procedure only), and the primary endpoint is a short-term postoperative complication (delayed gastric emptying), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma. PMID 39722558 · CPT Pharmacometrics Syst Pharmacol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of narrative versus non-narrative pictorial warning labels on visual attention and alcohol-related cancer risk perceptions: An eye-tracking study. PMID 39671807 · Addict Behav · 2025-Mar The record describes a randomized eye-tracking study on alcohol warning labels and cancer risk perceptions, not a clinical trial with a drug intervention or a time-to-event efficacy endpoint. Therefore, it does not meet the core eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in non-small cell lung cancer: psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials. PMID 39636512 · Qual Life Res · 2025-Mar The report is a psychometric evaluation of patient-reported outcome (PRO) measures (PROMIS PF-SF and NSCLC-SAQ) using data from two Phase 3 trials. It does not report time-to-event efficacy outcomes (OS, PFS, etc.) or analyze drug intervention efficacy. The publication type and content indicate a methodological/psychometric study, not a primary efficacy result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of KH903 Plus FOLFIRI as a Second-Line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study. PMID 39632230 · Clin Colorectal Cancer · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Influence of the type of anaesthesia on acute kidney injury after nephrectomy: a randomised controlled trial. PMID 39592204 · Anaesthesia · 2025-Mar The record is a randomized trial in oncology patients with a drug intervention, but the primary efficacy endpoint is acute kidney injury (a safety/toxicity endpoint), not a time-to-event oncologic efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No time-to-event data (Kaplan-Meier, HR) are reported for any oncologic endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. PMID 39585603 · Qual Life Res · 2025-Mar The record describes a psychometric validation study of a symptom assessment form within a Phase III trial, not a report of the trial's drug efficacy results. It does not contain the required primary or key secondary time-to-event endpoint data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. PMID 39576946 · J Clin Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial. PMID 39565556 · Qual Life Res · 2025-Mar The report is a secondary analysis of a Phase III randomized trial in prostate cancer, focusing on quality of life and testosterone recovery. It does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Additionally, the intervention (ADT) is standard hormonal therapy, not a novel drug intervention meeting the criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. PMID 39561384 · J Urol · 2025-Mar The record describes a long-term follow-up analysis of a single-arm Phase III trial. It is an original report with drug intervention and oncology setting, but it lacks a randomized comparator and does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. The primary endpoint of the original trial appears to be complete response rate (a binary outcome). Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY. PMID 39520048 · Br J Clin Pharmacol · 2025-Mar The record is from a randomized trial (RUBY) that meets many criteria but does not explicitly state the phase as Phase III/IIIb or Phase II/III in the provided metadata. The deterministic review flagged this as 'phase3_evidence_unclear'. The report's primary focus is pharmacokinetics and exposure-response, not the formal primary efficacy analysis of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. PMID 39505259 · J Thorac Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of ultrasound-guided bilateral rectus sheath block vs. local anesthetic infiltration in gynecologic oncology patients undergoing midline laparotomy: a triple-blinded randomized controlled trial. PMID 39480232 · Minerva Anestesiol · 2025-Mar The record describes a randomized controlled trial comparing two local anesthetic techniques for postoperative pain management in gynecologic oncology surgery. While it is a randomized trial in human oncology patients, it does not meet several key eligibility criteria: the phase is not established as Phase III/IIIb or Phase II/III, the intervention is a non-drug-only procedural technique (ultrasound-guided rectus sheath block vs. local anesthetic wound infiltration), and the primary endpoints are pain scores and analgesic consumption, which are not time-to-event efficacy outcomes (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial. PMID 39462182 · BJU Int · 2025-Mar This is an original, randomized, oncology trial reporting primary results. However, it is excluded because it does not involve a drug-containing intervention (it compares surgical techniques) and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, with KM or HR). The 'recurrence rates' mentioned are not presented as KM curves or with a hazard ratio.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer. PMID 39332930 · Eur Urol · 2025-Mar Oncology human randomized Phase III trial with original result, but excluded due to lack of time-to-event endpoint signal and apparent non-drug-only intervention (radiation fractionation comparison).
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. PMID 39304427 · Eur Urol · 2025-Mar The report describes a secondary analysis of a randomized controlled trial in oncology. While it is human, oncology, randomized, and reports a time-to-event endpoint (local event-free survival), it lacks a drug-containing intervention (radiotherapy is a non-drug intervention) and the primary endpoint is not a key efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ten-Year Survivals of Right Thoracic vs Left Thoracic Approach for Esophageal Cancer. PMID 39293749 · Ann Thorac Surg · 2025-Mar The study is a randomized trial in human oncology with primary time-to-event endpoints, but it compares two surgical approaches (right vs. left thoracic) and does not involve a drug-containing intervention. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Robotic-assisted versus conventional laparoscopic surgery for endometrial cancer: long-term results of a randomized controlled trial. PMID 39181495 · Am J Obstet Gynecol · 2025-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and safety of concurrent radiotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized controlled trial. PMID 40672085 · J Gastrointest Oncol · 2025-Jun-30 The trial is an oncology RCT with drug intervention and time-to-event endpoints (OS, PFS), but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review code 'phase3_evidence_unclear' indicates uncertainty. Without explicit phase information, eligibility cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO). PMID 40672074 · J Gastrointest Oncol · 2025-Jun-30 The study is a randomized, drug-intervention trial in oncology with a time-to-event secondary endpoint (PFS) and original results. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata, and the primary endpoint is treatment adherence, not an efficacy endpoint as required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study. PMID 40642487 · Chin J Cancer Res · 2025-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of mailed surveillance invitations and telephone patient navigation to improve hepatocellular carcinoma surveillance uptake: study protocol of VIGILANT-a single-centre, two-arm randomised controlled trial. PMID 40588390 · BMJ Open · 2025-Jun-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A mobile supportive care app for patients with metastatic lung cancer: the Lung Cancer App (LuCApp) randomized controlled trial. PMID 40586961 · Support Care Cancer · 2025-Jun-30 The study is a randomized trial in oncology with a time-to-event endpoint, but it does not involve a drug-containing intervention (it tests a mobile app for symptom monitoring) and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial. PMID 40579605 · Cancer Chemother Pharmacol · 2025-Jun-28 The abstract describes a randomized trial in metastatic breast cancer with a drug intervention (metformin + chemotherapy) and reports original results. However, it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier analysis. The primary outcome appears to be IGF-1 level changes, and the secondary outcome is disease progression (a binary outcome), not a time-to-event endpoint. Therefore, it does not meet the key criterion for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer. PMID 40571867 · J Gastrointest Cancer · 2025-Jun-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Selective neoadjuvant therapy of rectal cancer patients (SELREC): study protocol for a European randomised controlled, open, multicentre non-inferiority trial. PMID 40578870 · BMJ Open · 2025-Jun-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial]. PMID 40550657 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Jun-25 The study is a randomized Phase III trial in human oncology (rectal cancer) with primary results. However, it is ineligible because the intervention is a surgical technique comparison (not a drug-containing intervention), and the primary endpoint is a quality-of-life/functional outcome (LARS score), not a time-to-event efficacy endpoint as defined by the criteria (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analysis of such).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi. PMID 40106688 · Blood Adv · 2025-Jun-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. PMID 40551254 · Breast Cancer Res · 2025-Jun-23 The study meets oncology, human, randomized, time-to-event, drug intervention, and original result criteria. However, the phase of the trial (III/IIIb or II/III) is not explicitly confirmed in the provided metadata or abstract text. The abstract references a trial registration (NCT01042379) but does not specify the phase. Therefore, the 'phase3_or_definitive' criterion cannot be established, and the record is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -